Sequential high-dose cytosine arabinoside and L-asparaginase in childhood leukemia in relapse. 1985

L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females

Related Publications

L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
July 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
January 1982, Medical and pediatric oncology,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
January 1985, Sangre,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
November 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
April 1998, Medical and pediatric oncology,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
October 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
January 1987, Sangre,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
June 1990, Cancer,
L J Ettinger, and R Biener, and J Z Finklestein, and P Kamalakar, and G R Jones, and V I Avramis, and J S Holcenberg
January 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!